Alvotech (ALVO) Q2 FY26 earnings call

Alvotech navigated a challenging first half marked by manufacturing slowdowns due to facility improvements and regulatory resubmissions. With these critical activities concluded and FDA inspections successfully closed, the company is poised for a strong second half, particularly Q4, driven by normalizing supply and an expanding commercial portfolio. Strategic equity financing and pipeline advancements underpin the company's long-term growth trajectory, focusing on future launches and market diversification.